Interactive Drug Benefit List
DIN/NPN/PIN 02379201 MYLAN-RIZATRIPTAN ODT 10 MG ORAL DISINTEGRATING TABLET RIZATRIPTAN BENZOATE
280000 CENTRAL NERVOUS SYSTEM AGENTS
283200 ANTIMIGRAINE AGENTS
283228 SELECTIVE SEROTONIN AGONISTS
Date Listed/Coverage Update: 01-May-2012
Unit Price: 3.7050
LCA Price: 2.8150
MAC Price:

N/A

Unit of Issue: Tablet
Manufacturer: VIATRIS CANADA (MYLAN PHARMACEUTICALS ULC) (MYP)
ATC: N02CC04
1
Interchangeable Products: Yes

Coverage Status: RESTRICTED BENEFIT/ SPECIAL AUTHORIZATION
Applies to Clients of: Non-Group Coverage (Group 1)
Coverage for Seniors (Group 66)
Palliative Coverage (Group 20514, Please note your client may have Group 1 or Group 66 coverage)
Child and Family Services (Group 20403)
Alberta Child Health Benefit (Group 20400)
Children and Youth Services (Group 19824)
Income Support (Group 19823)
Alberta Human Services (AISH) (Group 19823)
Alberta Adult Health Benefit (AAHB) (Group 23609)

Special Authorization Request Form:

Drug Special Authorization Request Form (ABC 60015)

ALBERTA HEALTH RESTRICTED BENEFIT

This product is a benefit for patients 18 to 64 years of age inclusive for the treatment of acute migraine attacks in patients where standard therapy has failed. (Refer to Criteria for Special Authorization of Select Drug Products of the List for eligibility in patients 65 years of age and older; and Criteria for Special Authorization of Select Drug Products of the Alberta Human Services Drug Benefit Supplement for eligibility in Alberta Human Services clients.)


ALBERTA HEALTH SPECIAL AUTHORIZATION

(Refer to 28:32.28 of the Alberta Drug Benefit List for coverage of patients 18 to 64 years of age inclusive.)

"For the treatment of acute migraine attacks in patients 65 years of age and older where other standard therapy has failed."

"For the treatment of acute migraine attacks in patients 65 years of age and older who have been using rizatriptan benzoate prior to turning 65."

"Special authorization for both criteria may be granted for 24 months."

In order to comply with the first criteria, information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.


ALBERTA HUMAN SERVICES SPECIAL AUTHORIZATION

"For the treatment of acute migraine attacks in patients where other standard therapy has failed. Special authorization may be granted for 24 months."

Information is required regarding previous medications utilized and the patient's response to therapy.

The following product(s) are eligible for auto-renewal.

Review Status / Past Decisions

Indication Reviewing
Body
Submission
Completion
Date
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
CDR
Recommendation
Review
Status
N/A Expert Committee 2012/02/15 2012/05/01 Restricted Benefit/Special Authorization
N/A Expert Committee 2012/02/15 2012/05/01 Restricted Benefit/Special Authorization
N/A Expert Committee 2012/02/15 2012/05/01 Restricted Benefit/Special Authorization
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2012/02/15
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2012/05/01
CDR
Recommendation
Review
Status
Restricted Benefit/Special Authorization
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2012/02/15
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2012/05/01
CDR
Recommendation
Review
Status
Restricted Benefit/Special Authorization
Indication N/A
Reviewing
Body
Expert Committee
Submission
Completion
Date
2012/02/15
CDR
Recommendation
Date
Expert Committee
Recommendation
Date
ADBL
Effective
Date
2012/05/01
CDR
Recommendation
Review
Status
Restricted Benefit/Special Authorization
To return to the printable Drug Benefit List and related publications, click here
Last Updated:
NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.
Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.
Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.